Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

MIRA | Mira Pharmaceuticals Inc

Healthcare | Drug Manufacturers - General | USA | NASD

Index	-	P/E	-	EPS (ttm)	-	Insider Own	30.54%	Shs Outstand	14.75M	Perf Week	8.05%
Market Cap	69.32M	Forward P/E	-	EPS next Y	-	Insider Trans	6.53%	Shs Float	10.24M	Perf Month	-23.95%
Income	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float / Ratio	0.06% / 0.05	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Interest	0.01M	Perf Half Y	-
Book/sh	0.08	P/B	58.05	EPS next Y	-	ROA	-	Target Price	-	Perf Year	-
Cash/sh	0.00	P/C	3466.25	EPS next 5Y	-	ROE	-	52W Range	3.00 - 7.98	Perf YTD	-36.66%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-41.10%	Beta	-
Dividend %	-	Quick Ratio	0.03	Sales past 5Y	0.00%	Gross Margin	-	52W Low	56.67%	ATR	0.68
Employees	-	Current Ratio	0.03	Sales Q/Q	-	Oper. Margin	-	RSI (14)	42.97	Volatility	8.47% 17.98%
Optionable	No	Debt/Eq	1.61	EPS Q/Q	-2097.44%	Profit Margin	-	Rel Volume	0.09	Prev Close	4.67
Shortable	Yes	LT Debt/Eq	0.04	Earnings	-	Payout	-	Avg Volume	138.51K	Price	4.70
Recom	-	SMA20	-2.25%	SMA50	-17.35%	SMA200	-17.35%	Volume	12,678	Change	0.64%

Sep-18-23 08:30AM	MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than Pot (PR Newswire) +38.80%
Sep-05-23 08:31AM	MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication Efforts (PR Newswire)
Aug-31-23 08:31AM	MIRA Pharmaceuticals to Participate in 6th Annual Cannabinoid-Derived Drug Development Summit (PR Newswire)
Aug-29-23 11:39AM	MIRA Pharmaceuticals to Host Virtual Roadshow Webinar on Monday, September 11, 2023 at 1:00 p.m. Eastern Time (PR Newswire)
Aug-09-23 09:35AM	MIRA Pharmaceuticals, Inc. Discusses Potential of Revolutionary THC Analog Drug, MIRA1a, with The Stock Day Podcast (ACCESSWIRE)
02:40PM	Loading…
Aug-03-23 02:40PM	MIRA Pharmaceuticals debuts on the Nasdaq with plans to revolutionize medicinal CBD and THC (News Direct)

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company engages in developing its product candidate, MIRA1a, as a synthetic cannabinoid analog for treating anxiety & chronic pain by targeting the cannabinoid type 1 and type 2 (CB1 and CB2) receptors. MIRA Pharmaceuticals was founded by Adam Kaplin on September 3, 2020 and is headquartered in Baltimore, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cappy George	10% Owner	Aug 07	Buy	7.00	119,048	833,336	2,859,318	Aug 24 05:38 PM
Cappy George	10% Owner	Aug 02	Buy	7.00	157,170	1,100,190	2,740,270	Aug 04 01:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MIRA | Mira Pharmaceuticals Inc

Upgrade your FINVIZ experience